2022
How often is each gene mutated within the cancer patient population?
Mendiratta G, Jones M, Stites E. How often is each gene mutated within the cancer patient population? Molecular & Cellular Oncology 2022, 9: 2065176. PMID: 35529901, PMCID: PMC9067461, DOI: 10.1080/23723556.2022.2065176.Peer-Reviewed Original Research
2020
A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors
McFall T, Stites E. A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors. Molecular & Cellular Oncology 2020, 7: 1701914. PMID: 32158916, PMCID: PMC7051129, DOI: 10.1080/23723556.2019.1701914.Peer-Reviewed Original ResearchEpidermal growth factor receptorKRAS mutationsColorectal cancer patients treated with cetuximabPhase 3 clinical trial dataResistance to epidermal growth factor receptorPatients treated with cetuximabCancer personalized medicineColorectal cancer patientsGrowth factor receptorFactor receptorCancer patientsKRASCancer cellsAspartic acid mutationAmino acid 13NRAS signalingTrial dataPatientsCetuximabPersonalized medicineTumor suppressorMutationsImpaired bindingAcid mutationsExperimental biology
2017
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramanathan R, Weiss G, Posner R, Rajeshkumar N, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites E, Hlavacek W, Gatalica Z, Xiu J, Hidalgo M, Von Hoff D, Barrett M. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal Of Gastrointestinal Oncology 2017, 8: 925-935. PMID: 29299351, PMCID: PMC5750179, DOI: 10.21037/jgo.2017.09.05.Peer-Reviewed Original ResearchMetastatic pancreatic cancer patientsPancreatic cancer patientsCancer patientsNon-cross-resistant regimensExcision repair cross-complementation group 1 proteinPhase II studyPhase 2 trialEfficacy of therapyBased treatment strategiesImmunohistochemistry targetingInsufficient tumorStudy therapyLine therapyMedian survivalCytotoxic therapyMetastatic lesionsCancer related symptomsTumor biopsiesII studyPercutaneous biopsyTumor immunohistochemistryTreatment regimensTreatment strategiesBiopsyRegimens
2012
The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology
Stites E. The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology. Science Signaling 2012, 5: pe46. PMID: 23074264, DOI: 10.1126/scisignal.2003354.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorBRAF(V600E) mutationAmount of epidermal growth factor receptorEpidermal growth factor receptor inhibitorsBRAF inhibitor vemurafenibColon cancer patientsGrowth factor receptorCancer systems biologyFunctional genomics approachDecreased negative feedbackMelanoma patientsClinical responseBRAF inhibitionInhibitor vemurafenibTreatment optionsColon cancerClinical evaluationFactor receptorCancer patientsCombined treatmentBRAF(V600EVemurafenibGenomic approachesSystems biologyCancer